While Atea Pharmaceuticals Inc has overperformed by 0.70%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVIR fell by -21.80%, with highs and lows ranging from $4.14 to $2.60, whereas the simple moving average fell by -13.52% in the last 200 days.
On August 13, 2024, Morgan Stanley Upgraded Atea Pharmaceuticals Inc (NASDAQ: AVIR) to Equal-Weight. A report published by JP Morgan on August 10, 2023, Downgraded its rating to ‘Underweight’ for AVIR. Morgan Stanley also Downgraded AVIR shares as ‘Underweight’, setting a target price of $7 on the company’s shares in a report dated January 06, 2022. JP Morgan October 20, 2021d its ‘Overweight’ rating to ‘Neutral’ for AVIR, as published in its report on October 20, 2021. Morgan Stanley’s report from October 05, 2021 suggests a price prediction of $55 for AVIR shares, giving the stock a ‘Equal-Weight’ rating. Evercore ISI also rated the stock as ‘Outperform’.
Analysis of Atea Pharmaceuticals Inc (AVIR)
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Atea Pharmaceuticals Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -33.88% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 24.85, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and AVIR is recording an average volume of 336.08K. On a monthly basis, the volatility of the stock is set at 6.70%, whereas on a weekly basis, it is put at 5.40%, with a loss of -4.33% over the past seven days. Furthermore, long-term investors anticipate a median target price of $6.00, showing growth from the present price of $2.87, which can serve as yet another indication of whether AVIR is worth investing in or should be passed over.
How Do You Analyze Atea Pharmaceuticals Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 21.44%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 63.30% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AVIR shares are owned by institutional investors to the tune of 63.30% at present.
